Loading ETF profile…
The Invesco NASDAQ Future Gen 200 ETF (the Fund) aims to provide exposure to the Nasdaq Innovators Completion Cap Index (the Index). To achieve this, the Fund allocates at least 90% of its total assets to the securities that comprise the Index. The Index itself is composed of 200 small-capitalization companies, which Nasdaq selects based on the relative value of their patent portfolios compared to their overall market capitalization. These eligible companies are drawn from the Nasdaq Composite Index, specifically excluding those already included in the Nasdaq-100 Index and Nasdaq Next Generation 100 Index. Every company within the Index is equally weighted. Both the Fund and the Index are updated regularly, with rebalancing occurring quarterly and reconstitution happening semi-annually.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| NWL | Newell Brands Inc | 0.89% | $187.58K |
| ARQQ | Arqit Quantum Inc | 0.82% | $174.10K |
| CLPT | ClearPoint Neuro Inc | 0.76% | $161.39K |
| CYBN | Cybin Inc | 0.75% | $159.13K |
| QTRX | Quanterix Corp | 0.74% | $156.14K |
| MYGN | Myriad Genetics Inc | 0.73% | $155.08K |
| OCC | Optical Cable Corp | 0.72% | $152.56K |
| QDEL | QuidelOrtho Corp | 0.70% | $147.35K |
| TLSI | TriSalus Life Sciences Inc | 0.69% | $146.29K |
| FCEL | FuelCell Energy Inc | 0.68% | $144.80K |
| PGEN | Precigen Inc | 0.68% | $143.56K |
| LGND | Ligand Pharmaceuticals Inc | 0.67% | $142.57K |
| XNCR | Xencor Inc | 0.65% | $138.20K |
| TXG | 10X Genomics Inc | 0.65% | $138.12K |
| AGIO | Agios Pharmaceuticals Inc | 0.64% | $136.18K |
| — | Rigel Pharmaceuticals Inc | 0.64% | $134.77K |
| QTTB | Q32 Bio Inc | 0.64% | $134.67K |
| — | Cartesian Therapeutics Inc | 0.64% | $134.56K |
| MLKN | Millerknoll Inc | 0.63% | $133.09K |
| ENTG | Entegris Inc | 0.61% | $129.65K |
| ATEC | Alphatec Holdings Inc | 0.61% | $129.01K |
| QMCO | Quantum Corp | 0.61% | $128.44K |
| CVLT | Commvault Systems Inc | 0.60% | $127.74K |
| LXRX | Lexicon Pharmaceuticals Inc | 0.60% | $127.45K |
| ZVRA | Zevra Therapeutics Inc | 0.60% | $127.22K |